Issuu on Google+

Пациентам  с  диагнозом  Мигрень    

Возможно,  пора   оглядеться  вокруг  и   For Intractable Chronic Migraine Patients, перестать   мыслить   Is it Time to Think шаблонно?   Outside the Box?  

 


Intr actable chronic migr aine can be a challenge to treat. Peripher al

Стимуляция Периферических нервов – nerve stimulation (PNS) of the occipital(Затылочных) nerves, sometimes referred to Доказанная технология, значительные преимущества.

as occipital nerve stimulation, has emerged as an advanced, non-drug

 

ther apy to help patients manage this debilitating condition. Intr actable chronic migr aine can be a challenge treat. Peripher Упорная   мигрень   тяжело   поддается   лечению.  to Преимущество   в   al

лечении  –  у(PNS)  лекарственной   терапии,   но  она  sometimes может  оказаться   не   to nerve stimulation of the occipital nerves, referred

эффективной   для  многих   пациентов,   аже  ухудшая   симптомы   as occipital nerve stimulation, has emergedиногда   as an дadvanced, non-drug

из-­‐за  побочных  эффектов  или  слишком  длительного  применения.  Для  

ther apy tochronic help patients manage this debilitating A Proven Technology With Significant Advantages Intr actable migr aine can be a challenge to condition. treat. Peripher al таких   пациентов,   невосприимчивых   к  лекарственной   терапии,   St  Jude  

Medical    предлагает   новую,   опробованную   технологию   –  сreferred тимуляция   nerve stimulation (PNS) of the occipital nerves, sometimes to

нneurostimulation ервов  (PNS).    emerged В  терапии   пhave рименяется   ебольшая   For more 30 периферических   years, St.nerve Jude Medical’s for SCS used to н manage intractable asthan occipital stimulation, hassystems as anbeen advanced, non-drug

система,  которую   размещают   под   ожей   для   chronic pain ofther theимплантируемая   trunk This well-established platform is now approved for useкfor the management of apyand tolimbs. help patients manage this debilitating condition. стимуляции   з атылочных   н ервов.     and disability associated with intractable chronic migraine. ApainProven Technology With Significant Advantages  

A randomized, double-blind, controlled study ofисследований, chronic migraine sufferers who used St. Jude Medical По данным последних проведенных при поддержке

St

1 neurostimulation systems revealed the Jude Medical, на following: фоне PNS сокращается количество дней с головными For more than 30 years, St. Jude Medical’s neurostimulation systems for SCS have been used to manage intractable

1

болями месяц как следствие улучшается качество жизни. chronic pain of the trunk andвlimbs. Thisиwell-established is now approved for use for the management of A Proven Technology With Significant platform Advantages pain and disability associated with intractable chronic migraine. Reduction in Overall Disability 100% 80% 60% 40% 20% 0% Снижение   общей   12 weeks, the Migraine Disabilitycontrolled Assessmentstudy (MIDAS) AAtrandomized, double-blind, of chronic migraine sufferers who used St. Jude Medical For more than 30 years, St. Jude Medical’s neurostimulation systems for SCS have been used to manage intractable недееспособности .     1 questionnaire indicated that participants the following: active group Active neurostimulation systems revealedinthe 41% pain of Согласно   the trunkdisability and limbs. опросу   MThis IDAS   Migraine   platform is now approved for use for the management of hadchronic a 41% reduction in overall compared towell-established a(13% Control 13% pain and disability associated with intractable chronic migraine. Disability   Assessment   –  анкета   reduction in the control group. Reduction in Overall Disability

оценки  недееспособности  

Reduction in Overall Disability controlled study of chronic migraine sufferers who used St. Jude Medical A randomized, double-blind, вследствие  мигрени),  общее  1 100% 80% 60% 40% 20% At 12 weeks, the Migraine Disabilityrevealed Assessment neurostimulation systems the(MIDAS) following: состояние   участников   12-­‐ questionnaire that participants in the active group Reduction inindicated Headache Days Active 41%

тинедельного  исследования  

had a 41% reduction overall disability compared to a 13% At 12 weeks, patientsinwho received stimulation reported a улучшилось  на  41%,  в   reduction in the control group. 36% decrease in their number of headache days compared Reduction in Overall Disability группе  этот   контрольной   to the control group, which reported 25% decrease. At 12 weeks, the Migraine Disabilitya Assessment (MIDAS)

процент  составил  13%.      

questionnaire indicated that participants in the active group   had a 41% in overall Reduction in reduction Headache Days disability compared to a 13% Сокращение   дней  с   reduction the control At 12 weeks, in patients who group. received stimulation reported a

болью.   Quality of Lifein theirголовной   36% decrease number of headache days compared

Участники   и у   1 year, 68% of patients reported that decrease. their toAtthe control group, which reported a сследования,   25% которых   п рименялась   quality of life improved, 26%Days reported that it Reduction in Headache нейростимуляция,   stayed the same, and 5% reported theirотмечали   At 12 weeks, patients who receivedthat stimulation reported a снижение   к оличества   дней  с   quality life deteriorated. 36%of decrease in their number of headache days compared головными  болями  на  36%  за   срок  12  недель,  контрольная   At 1 year, 68% of patients reported that their группа  отмечала  снижение  на   quality of life improved, 26% reported that it 25%.     to theofcontrol Quality Life group, which reported a 25% decrease.

stayed the same, and 5% reported that their   quality of life Quality ofdeteriorated. Life

PNS therapy provides other benefits as well:   Качество   жизни.  

100%

80%

60%

40%

20%

Control Active Control

100%

Reduction in Overall36% Disability 80%

80%

Active 0%

Deteriorated Active

60%

40% 25%

20%

100%

20% 13%

60%

40%

40%

36% 60%

Reduction in Overall Disability

20%

80%

25% 68% Reduction in Headache Days 80% 60% 40% 26%

5%

Control 0%

0%

0% 100%

 

20%

0%

36%

Quality of Life

20%

40%

25%80%

60%

100%

Reduction in Headache Days 68%

Improved Same Deteriorated

0%

Reduction in Headache 41% Days

Control 100%

Same

0%

13%

Active

Control Improved

 

26% 5% 0%

20%

40%

60%

At 1 year, 68% of patients reported that their Quality of Life год  пreported рименения   Patients tryЧерез   PNS before having athat permanent system implanted, so they can know what to expect. quality ofcan life improved, 26% it 68% Improved стимуляции   68%   ациентов   stayed are the placed same, and 5% reported thatпtheir Leads in a minimally invasive procedure. Same 26% отмечали,  что  они  улучшили   quality of life deteriorated.

80%

5% Deteriorated if desired. 5%  оand тмечали,   The system canкачество   be turned ж offизни,   at any2time completely removed, Quality of Life что  other качество   жизни   не   PNS therapy provides benefits as well: Patients can continue to receive ongoing care from their headache specialist. изменилось,  5%  отметили,  что   Patients can try PNS before having a permanent system implanted, so they can know what to expect.

качество  жизни  ухудшилось.    

Leads are placed   in a minimally invasive procedure. PNSsystem therapy provides other as well: The can be turned offbenefits at any time and completely removed, if desired. Patients try PNS a permanent system implanted, so they can know what to expect. Patients cancan continue to before receivehaving ongoing care from their headache specialist. Leads are placed in a minimally invasive procedure. The system can be turned off at any time and completely removed, if desired.

100%

 


life improved, 26% reported that it stayed the same, and 5% reported that their quality of life deteriorated.

68%

Improved Same Deteriorated

26% 5% Quality of Life

1. Silberstein S, Dodick D, Saper J, et al. The safety and efficacy of peripheral nerve stimulation of the occipital nerve for the management of chronic migraine. Poster presented at: 15th Congress of the International Headache Society; June 23-26, 2011; Berlin, Germany.

ATRIAL FIBRILLATION Global Headquarters One St. Jude Medical Drive St. Paul, Minnesota 55117 USA +1 651 756 2000 +1 651 756 3301 Fax

CARDIAC RHYTHM MANAGEMENT Neuromodulation Division 6901 Preston Road Plano, Texas 75024 USA +1 972 309 8000 +1 972 309 8150 Fax

CARDIOVASCULAR

SJM Coordination Center BVBA The Corporate Village Da Vincilaan, 11 Box F1 1935 Zaventem Belgium +32 2 774 68 11 +32 2 772 83 84 Fax

NEUROMODULATION

St. Jude Medical Australia Pty. Ltd. 17 Orion Road Lane Cove NSW 2066 Australia +61 2 9936 1200 +61 2 9936 1222 Fax

(GMNMD76EN)

sjmneuropro.com   представитель  компании    

119002  Москва,   Карманицкий  пер.  д.9,   CE marking Б does not necessarily indicate regulatory approval status for all markets. Please refer to the instructions for use for a full listing of indications, contraindications, Арбат   изнес   Центр,   оф.  701   warnings and precautions. Отдел   Нейромодуляции   ST. JUDE MEDICAL, the nine-squares symbol, and MORE CONTROL. LESS RISK are registered and unregistered trademarks and service marks of St. Jude Medical Inc. and its related companies. ©2012 St. Jude Medical Neuromodulation Division. All rights reserved. Тел:   (495)  234  91  19   Item GMNMD76EN Факс:  (495)  232  26  55   e-­‐mail:  info@implanta.ru  


migren